<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556931</url>
  </required_header>
  <id_info>
    <org_study_id>J15165</org_study_id>
    <secondary_id>IRB00080399</secondary_id>
    <secondary_id>P01CA015396</secondary_id>
    <nct_id>NCT02556931</nct_id>
  </id_info>
  <brief_title>Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies</brief_title>
  <official_title>Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell&#xD;
      transplant in certain malignancies that are considered difficult to engraft.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal is to learn whether a drug called tacrolimus, which is an immune-lowering drug&#xD;
      (an immunosuppressant) given after transplant to help prevent certain complications, can be&#xD;
      given safely for a shorter period of time than it has been in the past. The experiences with&#xD;
      immunosuppression duration with other allogeneic HSCT platforms cannot be directly&#xD;
      extrapolated to the high-dose posttransplantation cyclophosphamide platform (another type of&#xD;
      immunosuppressant given after transplant to help prevent GVHD). There are presently no&#xD;
      published data on the minimum required duration of tacrolimus after nonmyeloablative HSCT&#xD;
      that includes high-dose Cy as part of postgrafting immunosuppression. The effectiveness of&#xD;
      high-dose posttransplantation Cy in GVHD prevention, however, permits the investigation of&#xD;
      this question. At the present time there are few or no cures for diseases studied on this&#xD;
      trial outside of a bone marrow or peripheral blood transplant. The peripheral blood for this&#xD;
      transplant comes from a relative who is a half-match or &quot;haplo&quot; match to the participant.&#xD;
      Possible donors include parents, siblings, and children. In order to help the bone marrow&#xD;
      grow, or &quot;take&quot;, inside the body, participants will receive chemotherapy and radiation before&#xD;
      the transplant. After the transplant participants will receive high doses of cyclophosphamide&#xD;
      (CytoxanÂ®) along with other medications to lower the immune system, such as tacrolimus. These&#xD;
      medications may lower the risk of graft versus host disease (GVHD) and of rejection of the&#xD;
      peripheral blood graft.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who are able to stop prophylactic tacrolimus (D90 cohort)</measure>
    <time_frame>Day 90</time_frame>
    <description>This outcome measures the feasibility of stopping prophylactic tacrolimus at Day 90.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who are able to stop prophylactic tacrolimus (D60 cohort)</measure>
    <time_frame>Day 60</time_frame>
    <description>This outcome measures the feasibility of stopping prophylactic tacrolimus at Day 60.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades III-IV acute GVHD, Days 90-180 (D90)</measure>
    <time_frame>Between Day 90 and Day 180</time_frame>
    <description>Percentage of participants who experience grade III or IV acute GVHD between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades III-IV acute GVHD, Days 60-180 (D60)</measure>
    <time_frame>Between Day 60 and Day 180</time_frame>
    <description>Percentage of participants who experience grade III or IV acute GVHD between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD, Days 90-180 (D90)</measure>
    <time_frame>Between Day 90 and Day 180</time_frame>
    <description>Percentage of participants who experience chronic GVHD requiring additional immunosuppressive therapy between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD, Days 60-180 (D60)</measure>
    <time_frame>Between Day 60 and Day 180</time_frame>
    <description>Percentage of participants who experience chronic GVHD requiring additional immunosuppressive therapy between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft failure, Days 90-180 (D90)</measure>
    <time_frame>Between Day 90 and Day 180</time_frame>
    <description>Percentage of participants who experience graft failure between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft failure, Days 60-180 (D60)</measure>
    <time_frame>Between Day 60 and Day 180</time_frame>
    <description>Percentage of participants who experience graft failure between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse, Days 90-180 (D90)</measure>
    <time_frame>Between Day 90 and Day 180</time_frame>
    <description>Percentage of participants who experience disease relapse between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse, Days 60-180 (D60)</measure>
    <time_frame>Between Day 60 and Day 180</time_frame>
    <description>Percentage of participants who experience disease relapse between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality, Days 90-180 (D90)</measure>
    <time_frame>Between Day 90 and Day 180</time_frame>
    <description>Percentage of participants who die for any reason other than disease relapse between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality, Days 60-180 (D60)</measure>
    <time_frame>Between Day 60 and Day 180</time_frame>
    <description>Percentage of participants who die for any reason other than disease relapse between Day 60 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 60 are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades III-IV acute GVHD, Day 360 (D90)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who experience grade III or IV acute GVHD by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades III-IV acute GVHD, Day 360 (D60)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who experience grade III or IV acute GVHD by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD, Day 360 (D90)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who experience chronic GVHD requiring additional immunosuppressive therapy by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD, Day 360 (D60)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who experience chronic GVHD requiring additional immunosuppressive therapy by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft failure, Day 360 (D90)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who experience graft failure by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft failure, Day 360 (D60)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who experience graft failure by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse, Day 360 (D90)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who experience disease relapse by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse, Day 360 (D60)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who experience disease relapse by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality, Day 360 (D90)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who die for any reason other than disease relapse by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality, Day 360 (D60)</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of participants who die for any reason other than disease relapse by Day 360. All participants are evaluable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <condition>Plasma Cell Dyscrasia</condition>
  <condition>Myelofibrosis</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Plasma Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>PBSCT D90</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBSCT D60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 60 or Day 180 depending on GVHD status.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Days -6 through -2: 30 mg/m^2 IV daily</description>
    <arm_group_label>PBSCT D60</arm_group_label>
    <arm_group_label>PBSCT D90</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily</description>
    <arm_group_label>PBSCT D60</arm_group_label>
    <arm_group_label>PBSCT D90</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Cy</other_name>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>Day -1: 200 cGy in a single fraction</description>
    <arm_group_label>PBSCT D60</arm_group_label>
    <arm_group_label>PBSCT D90</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.</description>
    <arm_group_label>PBSCT D60</arm_group_label>
    <arm_group_label>PBSCT D90</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>FK506</other_name>
    <other_name>FK-506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)</description>
    <arm_group_label>PBSCT D60</arm_group_label>
    <arm_group_label>PBSCT D90</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of a suitable related HLA-haploidentical or -matched stem cell donor, or a&#xD;
             10/10 matched unrelated donor&#xD;
&#xD;
          -  Eligible diagnoses: myelodysplastic syndrome (MDS) with at least 1 poor-risk feature;&#xD;
             small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) with 17p&#xD;
             deletion or with progression &lt; 6 months after a second or greater treatment regimen;&#xD;
             T-cell prolymphocytic leukemia (PLL) in partial response or better; interferon- or&#xD;
             tyrosine-kinase-refractory chronic myeloid leukemia (CML), or CML in second or&#xD;
             subsequent chronic phase; Philadelphia chromosome negative (Ph-) myeloproliferative&#xD;
             disease, including myelofibrosis; Multiple myeloma or plasma cell leukemia in partial&#xD;
             response or better; Hematologic malignancy in complete remission with minimal residual&#xD;
             disease (MRD) detectable by conventional cytogenetics, FISH, flow cytometry, or&#xD;
             molecular testing&#xD;
&#xD;
          -  Any previous autologous transplant must have occurred &gt; 3 months ago&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 35%, or shortening fraction &gt; 25%&#xD;
&#xD;
          -  Bilirubin &lt;= 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis)&#xD;
&#xD;
          -  AST and ALT &lt;= 5 x institutional upper limit of normal&#xD;
&#xD;
          -  FEV1 and FVC &gt;= 40% of predicted; if unable to perform pulmonary function testing,&#xD;
             oxygen saturation &gt; 92% on room air&#xD;
&#xD;
          -  ECOG performance status &lt;= 2, or Karnofsky/Lansky status &gt;= 60&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or active breastfeeding&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Previous allogeneic transplant&#xD;
&#xD;
          -  Active extramedullary leukemia or active central nervous system (CNS) malignant&#xD;
             disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy E DeZern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>410-502-7208</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunosuppression</keyword>
  <keyword>nonmyeloablative</keyword>
  <keyword>non-myeloablative</keyword>
  <keyword>allogeneic</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>peripheral blood</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Leukemia, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02556931/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

